

Reagan Building, Office of Agriculture and Food Security, 1300 Pennsylvania Avenue, NW., Room 2.11-005, Washington, DC 20523-2110, telephone him at (202) 712-5571 or fax (202) 216-3010.

**Tracy Atwood,**

*USAID Designated Federal Officer (Deputy Director, Office of Agriculture and Food Security, Center for Economic Growth and Agricultural Development, Bureau for Global Programs).*

[FR Doc. 99-3400 Filed 2-10-99; 8:45 am]

BILLING CODE 6116-01-M

International Development, Ronald Reagan Building, Office of Agriculture and Food Security, 1300 Pennsylvania Avenue, N.W., Room 2.11-055, Washington DC, 20523-2110, telephone him at (202) 712-5571 or fax (202) 216-3010.

**Tracy Atwood,**

*USAID Designated Federal Officer (Deputy Director, Office of Agriculture and Food Security, Economic Growth Center, Bureau for Global Programs).*

[FR Doc. 99-3399 Filed 2-10-99; 8:45 am]

BILLING CODE 6116-01-M

manufacturer of methylphenidate is in the public interest, the Chiragene's registration is not required to produce an adequate and uninterrupted supply of methylphenidate, that there is sufficient competition with the present bulk manufacturers and that there would be a public interest impact on reported trends of over-prescribing, abuse and diversion of methylphenidate.

The arguments of the objector were considered, however, DEA has reviewed the firm's safeguards to prevent the theft and diversion of methylphenidate and found that the firm has met the regulatory requirements and public interest factors of the Controlled Substances Act (CSA).

Chiragene has been investigated by DEA to determine if the firm maintains effective controls against diversion which included, in part, inspection and testing of the firm's physical security, verification of compliance with State and local law and a review of the firm's background. The investigation has found Chiragene to be in compliance with the CSA and its implementing regulations.

Under Title 21, Code of Federal Regulations, Section 1301.33(b), DEA is not required to limit the number of manufacturers solely because a smaller number is capable of producing an adequate supply provided effective controls against diversion are maintained. DEA has determined that effective controls against diversion will be maintained by Chiragene.

After reviewing all the evidence, DEA has determined, pursuant to 21 U.S.C., Section 823(a), that it is consistent with the public interest to grant Chiragene's application to manufacture methylphenidate and the other listed controlled substances at this time. Therefore, pursuant to 21 U.S.C., Section 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office Of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: January 25, 1999.

**John H. King,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 99-3403 Filed 2-10-99; 8:45 am]

BILLING CODE 4410-09-M

**INTERNATIONAL DEVELOPMENT COOPERATION AGENCY**

**Agency for International Development**

**Board for International Food and Agricultural Development, One Hundred and Twenty-Eighth Meeting; Notice of Meeting**

Pursuant to the Federal Advisory Committee Act, notice is hereby given of the one hundred and twenty-eighth meeting of the Board for International Food and Agricultural Development (BIFAD). The meeting will be held from 9:00 a.m. to 4:00 p.m. on February 25 and 26, 1999, both days, at the International Trade Center, Ronald Reagan Building, Meridian Suite, Room C, located at 1300 Pennsylvania Avenue, N.W., Washington DC, 20523.

As part of its agenda, BIFAD will discuss recent natural disasters; methods to improve soil fertility in selected areas of Africa; private-public partnerships and agribusiness opportunities in the developing world and; the Bio-Safety Protocol. The meeting is open to the public. Any interested person may attend the meeting, may file written statements with the Committee before or after the meeting, or present any oral statements in accordance with procedures established by the Committee, to the extent that time available for the meeting permits.

Those wishing to attend the meeting should contact Mr. George Like at the Agency for International Development, Ronald Reagan Building, Office of Agriculture and Food Security, 1300 Pennsylvania Avenue, N.W., Room 2.11-072, Washington DC, 20523-2110, telephone (202) 712-1436, fax (202) 216-3010 or internet [glike@usaid.gov] with your full name.

Anyone wishing to obtain additional information about BIFAD should contact Mr. Tracy Atwood the Designated Federal Officer for BIFAD. Write him in care of the Agency for

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated June 10, 1998, and published in the **Federal Register** on July 9, 1998, (63 FR 37137), Chiragene, Inc., 7 Powder Horn Drive, Warren, New Jersey 07509, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
N-Ethylamphetamine (1475) .....	I
2,5-Dimethoxyamphetamine (7396).	I
3,4-Methylenedioxyamphetamine (7400).	I
4-Methoxyamphetamine (7411) ..	I
Amphetamine (1100) .....	II
Methylphenidate (1724) .....	II

The firm plans to manufacture the listed controlled substances to supply their customers.

A registered bulk manufacturer of methylphenidate filed written comments and an objection in response to the notice of application. Review of the Administrative Procedures Act's (APA) definitions of license and licensing reveals that the granting or denial of a manufacturer's registration is a licensing action, not a rulemaking. Courts have frequently distinguished between agency licensing actions and rulemaking proceedings. See, e.g., *Gateway Transp. Co. v. United States*, 173 F. Supp. 822, 828 (D.C. Wis. 1959); *Underwater Exotics, Ltd. v. Secretary of the Interior*, 1994 U.S. Dist LEXIS 2262 (1994). Courts have interpreted agency action relating to licensing as not falling within the APA's rulemaking provisions.

The objector argues that Chiragene cannot prove its registration as a bulk